Kennedy Ferruggia, Assistant Editor

The results emphasize the need for pharmacists and health care providers to further educate patients about receiving recommended immunizations.

Gepotidacin could be first-in-class oral antibiotic treatment approved for uUTIs in over 20 years.

The trial met its primary endpoint of event-free survival, furthering treatment options for resected, locally advanced head and neck squamous cell carcinoma.

Female and older patients had a greater incidence of herpes zoster ophthalmicus and were more likely to develop ocular complications.

As the first dual neurokinin-1 and 3 receptor antagonist, elinzanetant could provide benefit for women suffering from vasomotor symptoms.

A single dose RSV vaccine per year can offer optimal protection against 3 full RSV seasons.

The addition of high-dose vitamin D3 to standard treatment did not delay the progression of cancer compared with the standard dose of vitamin D3.

Setrusumab could offer a rapid and clinically meaningful decrease in fracture rate in individuals with osteogenesis imperfecta.

The Inflation Reduction Act's zero cost-sharing policy resulted in significant increases in shingles vaccines dispensed to individuals under Part D, compared with those who are commercially insured.

Pharmacists and health care providers can counsel around vitamin D supplements and natural intake to increase a child’s vitamin D consumption.

RSV vaccination could be cost-effective among adults 60 years and older, with the ability to decrease vaccine costs and sustain efficacy.

Navenibart was developed to aid treatment of hereditary angioedema (HAE) to provide swift and sustained HAE attack prevention through administration every 3 to 6 months.

Adults with underlying medical conditions, resulting in an increased risk of respiratory syncytial virus disease are more likely to be cost-effective than general age-based strategies.

Vitamin D supplementation improved total cholesterol levels, systolic blood pressure, diastolic blood pressure, and all glycemic parameters.

If approved, delgocitinib cream would be the first US treatment indicated for moderate to severe chronic hand eczema.

Ponsegromab displayed significant and robust increases in body weight at the completion of the study for all doses.

Dermatomal reactions could occur following recombinant zoster vaccine to treat shingles.

Results displayed a non-inferior immune response of the co-administered vaccines, compared to administration in individual visits.

There is a need for continued research and awareness in the diagnosis and management of alopecia in diverse populations.

Not only do diverse clinical cohorts improve the strength of the data, but it improves public trust in clinicians and the medical system as a whole.

Immediate-early 62 enclosed inside small extracellular vesicles can transport from the site of infection, causing it to penetrate cells and shut down their antiviral response.

An overview of the potential treatment strategies for patients were presented at the 2024 World Conference on Lung Cancer.

Chronic fatigue is a related symptom with inflammatory bowel disease (IBD).

An overview of the latest developments in targeting DLL3 in lung neuroendocrine tumors were presented at the 2024 World Conference on Lung Cancer.

NS-050/NCNP-03 is being developed to aid individuals with confirmed gene mutations that are treatable with exon 50 skipping therapy.

Individuals with a history of shingles was significantly and independently connected with a 20% higher risk of for subjective cognitive decline.

RSV vaccination was 75% effective in preventing RSV-associated hospitalizations among adults aged 60 years and older.

There is no significant impact on maternal or infant health outcomes when taking an additional iron supplement

OBX-115 could offer further treatment options for individuals with advanced or metastatic melanoma by enhancing persistence, antitumor activity, and clinical safety of TIL cell therapy.

Shared clinical decision-making presented drawbacks, resulting in age-based recommendations for adults aged 75 years and older and risk-based recommendations for individuals aged 60-74 years.